Wollstonecraft, NSW, Australia;

“A world-first personalized mRNA cancer vaccine called intismeran, developed by Moderna and Merck with significant leadership from Australian researchers, has shown a 42% reduction in the risk of melanoma recurrence or death in a Phase 3 clinical trial.

The vaccine is designed for patients with high-risk melanoma (stages IIB to IV) who have undergone surgical removal of their tumor. It works by sequencing the patient’s unique tumor mutations to create a bespoke vaccine that trains the immune system to recognize and attack cancer cells, when used in combination with the immunotherapy drug pembrolizumab (Keytruda).

Key details include:

  • Trial Results: In the INTerpath-001 trial involving 1,137 patients, the combination therapy resulted in an 82% recurrence-free survival rate at two years, compared to 70% for immunotherapy alone.
  • Development: The trial was led by Professor Georgina Long of the Melanoma Institute Australia, marking a foundational shift in personalized cancer treatment.
  • Availability: The vaccine is currently investigational and not yet available as a standard treatment in Australia or globally. Regulatory submissions are expected, but widespread access will require further review and manufacturing setup.
  • Purpose: This is a therapeutic vaccine intended to prevent recurrence after surgery, not a preventative vaccine for healthy individuals.”

Recent Posts

Biology

Nature | Feral Hogs

Feral Hogs in Ameria; Image credit: USDA/APHIS/WS National Wildlife Research Center Archives. (n.d.). Feral swine…
Cats

Nature | Domestication of Cats

The Domestication of Cats; (this one is for Mo Mo (aka moo moo)) Photo of…
Adipose Tissue Cells

Diabetes News | Type 1, CiPSC Therapy

Peking, China; "Peking University researchers successfully reversed Type 1 diabetes in a 25-year-old Chinese woman…
Georgina Long

Cancer News, Melanoma, Intismeran

Wollstonecraft, NSW, Australia; "A world-first personalized mRNA cancer vaccine called intismeran, developed by Moderna and…
WeirdScience

Author WeirdScience

More posts by WeirdScience

Leave a Reply

Share